Replies to post #214529 on Biotech Values

[masterlongevity]

Interesting. I had no idea Eisai owned almost half of $biib #aducanumab

[DewDiligence]

BIIB pays $150M lump sum—reducing Aducanumab royalties payable to Neurimmune by 15%:

https://finance.yahoo.com/news/biogen-increases-profit-potential-investigational-102900129.html

As part of this amended agreement, Biogen also has an option to further reduce the royalty owed on potential commercial sales of aducanumab by an additional 5 percent in exchange for an additional one-time $50 million payment to Neurimmune Holding AG.